~~<i id='3E3703F488'><strike id='3E3703F488'><tt id='3E3703F488'><pre id='3E3703F488'></pre></tt></strike></i>~~

Home» focus» hotspot

hotspot

author：explore 2025-10-02 06:42:33 Page View：2977

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

FDA proposes changes to key medical devices approval pathway

Lastweek,theFDAreleasedatrioofguidelinesclarifyingthewaytheyplantoevaluatedevicesthatgothroughthe510

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

RaDonda Vaught links Vanderbilt hospital issues to patient death

RaDondaVaughtsitsinacourtroomaheadofhersentencinginNashville,Tenn.,onFriday,May13,2022.NicoleHester/